Actinium Pharmaceuticals Inc. (AMEX: ATNM) is 80.20% higher on its value in year-to-date trading and has touched a low of $4.41 and a high of $15.12 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ATNM stock was last observed hovering at around $10.24 in the last trading session, with the day’s gains setting it 0.59% off its average median price target of $25.00 for the next 12 months. It is also 79.57% off the consensus price target high of $53.00 offered by 6 analysts, but current levels are 39.83% higher than the price target low of $18.00 for the same period.
Currently trading at $10.83, the stock is -7.30% and 17.49% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.35 million and changing 5.76% at the moment leaves the stock 66.81% off its SMA200. ATNM registered 47.95% gain for a year compared to 6-month gain of 94.78%.
The stock witnessed a 36.74% loss in the last 1 month and extending the period to 3 months gives it a 67.13%, and is -7.12% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.07% over the week and 13.13% over the month.
Actinium Pharmaceuticals Inc. (ATNM) has around 32 employees, a market worth around $275.73M and $1.20M in sales. Distance from 52-week low is 145.58% and -28.37% from its 52-week high. The company has generated returns on investments over the last 12 months (-33.90%).
Actinium Pharmaceuticals Inc. (ATNM) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Actinium Pharmaceuticals Inc. (ATNM) is a “Buy”. 6 analysts offering their recommendations for the stock have an average rating of 1.80, where 0 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
The EPS is expected to grow by 34.20% this year
Actinium Pharmaceuticals Inc. (ATNM) Top Institutional Holders
The shares outstanding are 25.16M, and float is at 24.40M with Short Float at 1.99%.
Actinium Pharmaceuticals Inc. (ATNM) Insider Activity
A total of 1 insider transactions have happened at Actinium Pharmaceuticals Inc. (ATNM) in the last six months, with sales accounting for 0 and purchases happening 1 times.